1-5 of 5
Lovely Goyal, PhD
Close
Sort by
Journal Articles

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Sattva S. Neelapu, MD, Michael Dickinson, DMed Sci, Matthew L. Ulrickson, MD, Olalekan O. Oluwole, MBBS, MPH, Alex F. Herrera, MD, Catherine Thieblemont, MD PhD, Chaitra S. Ujjani, MD, Yi Lin, MD PhD, Peter A. Riedell, MD, Natasha Kekre, MD MPH, FRCPC, Sven de Vos, MD PhD, Yin Yang, MS, Francesca Milletti, PhD, Lovely Goyal, PhD, Jun Kawashima, MD, Julio C. Chavez, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 49.
https://doi.org/10.1182/blood-2020-134449
Published: 2020
Journal Articles

Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5

Julio C. Chavez, MD, Caron A. Jacobson, MD, Alison R. Sehgal, MD, Sattva S. Neelapu, MD, David G. Maloney, MD PhD, Gilles Salles, MD PhD, Basem M. William, MDMRCP, Yin Yang, MS, Lovely Goyal, PhD, Justin Chou, PhD, Vicki Plaks, LLB, PhD, Mauro P. Avanzi, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 34.
https://doi.org/10.1182/blood-2020-135871
Published: 2020
Journal Articles

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Caron A. Jacobson, MD, Frederick L. Locke, MD, David B. Miklos, MD PhD, Julie M. Vose, MD MBA, Yi Lin, MD PhD, Lihua E Budde, MD PhD, David G. Maloney, MD PhD, Samantha Jaglowski, MD MPH, Peter A. Riedell, MD, Lazaros J. Lekakis, MD, Miguel-Angel Perales, MD, Jenny J. Kim, MD MS, Jun Kawashima, MD, Yin Yang, MS, John M. Rossi, MS, Lovely Goyal, PhD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-136136
Published: 2020
Journal Articles

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Caron Jacobson, MD MMSc, Julio C. Chavez, MD, Alison R. Sehgal, MD, Basem M. William, MDMRCP, Javier Munoz, MD, Gilles Salles, MDPhD, Pashna N. Munshi, MD, Carla Casulo, MD, David Maloney, MD PhD, Sven de Vos, MD PhD, Ran Reshef, MD, Lori A. Leslie, MD, Ibrahim Yakoub-Agha, Olalekan O. Oluwole, MBBS, MPH, Henry C.H. Fung, MD, Joseph D. Rosenblatt, MD, John M. Rossi, MS, Lovely Goyal, PhD, Vicki Plaks, LLB, PhD, Yin Yang, MS, Jennifer Lee, BS, Wayne Godfrey, MD, Remus Vezan, MD PhD, Mauro P. Avanzi, MD PhD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-136834
Published: 2020
Journal Articles

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Sattva S Neelapu, MD, Mohamed A Kharfan-Dabaja, MDMBA, Olalekan O. Oluwole, MBBS, MPH, Patel Krish, MD, Ran Reshef, MDMSc, Peter A. Riedell, MD, Parveen Shiraz, MD, Patrick J. Stiff, MD, Jose Villasboas, MD, Lovely Goyal, PhD, Jun Kawashima, Francesca Milletti, PhD, Edward Oliva, Jennifer Sun, MS, Javier Munoz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4093.
https://doi.org/10.1182/blood-2019-126369
Published: 2019